Peringatan Keamanan

Data regarding overdose of naxitamab are unavailable. In the event of an overdose, patients should be treated with symptomatic and supportive measures.

Naxitamab

DB15965

biotech approved

Deskripsi

Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.L24454,A224604 Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within neuroblastomas (and other neuroectodermal tumors),A224609 and is rarely subject to antigen loss.A224604

The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was dinutuximab under the brand name Unituxin in 2015.A224474 One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA).L24929

Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.L24454 This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies,A224604 making the administration of naxitamab therapy markedly simpler than that of its predecessor.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean terminal half-life of naxitamab is 8.2 days.[L24454]
Volume Distribusi -
Klirens (Clearance) The clearance of naxitamab appears to be correlated inversely with body weight.[L24454]

Absorpsi

The mean plasma concentration of naxitamab following an intravenous infusion of 3 mg/kg over 30 minutes was 57.4 ?g/mL.L24454 The AUC of naxitamab appears to correlate with body size.A224474

Metabolisme

While the metabolism of naxitamab has not been studied directly,L24454 monoclonal antibodies as a class are principally metabolized to smaller peptides via catabolic processes.L24454,A216712

Rute Eliminasi

Monoclonal antibodies are typically eliminated via uptake into cells and subsequent catabolism via lysosomal degradation. Due to their large size, they are only eliminated renally under pathologic conditions.A216712

Interaksi Obat

661 Data
Valsartan Naxitamab may decrease the antihypertensive activities of Valsartan.
Ramipril Naxitamab may decrease the antihypertensive activities of Ramipril.
Esmolol Naxitamab may decrease the antihypertensive activities of Esmolol.
Betaxolol Naxitamab may decrease the antihypertensive activities of Betaxolol.
Reserpine Naxitamab may decrease the antihypertensive activities of Reserpine.
Remikiren Naxitamab may decrease the antihypertensive activities of Remikiren.
Torasemide Naxitamab may decrease the antihypertensive activities of Torasemide.
Bethanidine Naxitamab may decrease the antihypertensive activities of Bethanidine.
Guanadrel Naxitamab may decrease the antihypertensive activities of Guanadrel.
Metoprolol Naxitamab may decrease the antihypertensive activities of Metoprolol.
Isradipine Naxitamab may decrease the antihypertensive activities of Isradipine.
Olmesartan Naxitamab may decrease the antihypertensive activities of Olmesartan.
Chlorthalidone Naxitamab may decrease the antihypertensive activities of Chlorthalidone.
Nitroprusside Naxitamab may decrease the antihypertensive activities of Nitroprusside.
Atenolol Naxitamab may decrease the antihypertensive activities of Atenolol.
Diltiazem Naxitamab may decrease the antihypertensive activities of Diltiazem.
Minoxidil Naxitamab may decrease the antihypertensive activities of Minoxidil.
Timolol Naxitamab may decrease the antihypertensive activities of Timolol.
Treprostinil Naxitamab may decrease the antihypertensive activities of Treprostinil.
Amlodipine Naxitamab may decrease the antihypertensive activities of Amlodipine.
Nimodipine Naxitamab may decrease the antihypertensive activities of Nimodipine.
Nisoldipine Naxitamab may decrease the antihypertensive activities of Nisoldipine.
Bendroflumethiazide Naxitamab may decrease the antihypertensive activities of Bendroflumethiazide.
Prazosin Naxitamab may decrease the antihypertensive activities of Prazosin.
Fosinopril Naxitamab may decrease the antihypertensive activities of Fosinopril.
Trandolapril Naxitamab may decrease the antihypertensive activities of Trandolapril.
Metolazone Naxitamab may decrease the antihypertensive activities of Metolazone.
Lercanidipine Naxitamab may decrease the antihypertensive activities of Lercanidipine.
Benazepril Naxitamab may decrease the antihypertensive activities of Benazepril.
Bosentan Naxitamab may decrease the antihypertensive activities of Bosentan.
Propranolol Naxitamab may decrease the antihypertensive activities of Propranolol.
Clonidine Naxitamab may decrease the antihypertensive activities of Clonidine.
Enalapril Naxitamab may decrease the antihypertensive activities of Enalapril.
Doxazosin Naxitamab may decrease the antihypertensive activities of Doxazosin.
Labetalol Naxitamab may decrease the antihypertensive activities of Labetalol.
Cyclothiazide Naxitamab may decrease the antihypertensive activities of Cyclothiazide.
Bisoprolol Naxitamab may decrease the antihypertensive activities of Bisoprolol.
Candoxatril Naxitamab may decrease the antihypertensive activities of Candoxatril.
Nicardipine Naxitamab may decrease the antihypertensive activities of Nicardipine.
Guanabenz Naxitamab may decrease the antihypertensive activities of Guanabenz.
Mecamylamine Naxitamab may decrease the antihypertensive activities of Mecamylamine.
Losartan Naxitamab may decrease the antihypertensive activities of Losartan.
Moexipril Naxitamab may decrease the antihypertensive activities of Moexipril.
Phentolamine Naxitamab may decrease the antihypertensive activities of Phentolamine.
Furosemide Naxitamab may decrease the antihypertensive activities of Furosemide.
Eplerenone Naxitamab may decrease the antihypertensive activities of Eplerenone.
Lisinopril Naxitamab may decrease the antihypertensive activities of Lisinopril.
Nitroglycerin Naxitamab may decrease the antihypertensive activities of Nitroglycerin.
Metyrosine Naxitamab may decrease the antihypertensive activities of Metyrosine.
Hydroflumethiazide Naxitamab may decrease the antihypertensive activities of Hydroflumethiazide.
Cryptenamine Naxitamab may decrease the antihypertensive activities of Cryptenamine.
Perindopril Naxitamab may decrease the antihypertensive activities of Perindopril.
Candesartan cilexetil Naxitamab may decrease the antihypertensive activities of Candesartan cilexetil.
Tolazoline Naxitamab may decrease the antihypertensive activities of Tolazoline.
Fenoldopam Naxitamab may decrease the antihypertensive activities of Fenoldopam.
Indapamide Naxitamab may decrease the antihypertensive activities of Indapamide.
Tadalafil Naxitamab may decrease the antihypertensive activities of Tadalafil.
Alprenolol Naxitamab may decrease the antihypertensive activities of Alprenolol.
Eprosartan Naxitamab may decrease the antihypertensive activities of Eprosartan.
Chlorothiazide Naxitamab may decrease the antihypertensive activities of Chlorothiazide.
Quinapril Naxitamab may decrease the antihypertensive activities of Quinapril.
Omapatrilat Naxitamab may decrease the antihypertensive activities of Omapatrilat.
Phenoxybenzamine Naxitamab may decrease the antihypertensive activities of Phenoxybenzamine.
Pindolol Naxitamab may decrease the antihypertensive activities of Pindolol.
Telmisartan Naxitamab may decrease the antihypertensive activities of Telmisartan.
Methyldopa Naxitamab may decrease the antihypertensive activities of Methyldopa.
Hydrochlorothiazide Naxitamab may decrease the antihypertensive activities of Hydrochlorothiazide.
Guanfacine Naxitamab may decrease the antihypertensive activities of Guanfacine.
Trichlormethiazide Naxitamab may decrease the antihypertensive activities of Trichlormethiazide.
Felodipine Naxitamab may decrease the antihypertensive activities of Felodipine.
Irbesartan Naxitamab may decrease the antihypertensive activities of Irbesartan.
Nitrendipine Naxitamab may decrease the antihypertensive activities of Nitrendipine.
Deserpidine Naxitamab may decrease the antihypertensive activities of Deserpidine.
Pentolinium Naxitamab may decrease the antihypertensive activities of Pentolinium.
Trimethaphan Naxitamab may decrease the antihypertensive activities of Trimethaphan.
Diazoxide Naxitamab may decrease the antihypertensive activities of Diazoxide.
Carvedilol Naxitamab may decrease the antihypertensive activities of Carvedilol.
Bretylium Naxitamab may decrease the antihypertensive activities of Bretylium.
Terazosin Naxitamab may decrease the antihypertensive activities of Terazosin.
Guanethidine Naxitamab may decrease the antihypertensive activities of Guanethidine.
Rescinnamine Naxitamab may decrease the antihypertensive activities of Rescinnamine.
Acebutolol Naxitamab may decrease the antihypertensive activities of Acebutolol.
Captopril Naxitamab may decrease the antihypertensive activities of Captopril.
Nadolol Naxitamab may decrease the antihypertensive activities of Nadolol.
Epoprostenol Naxitamab may decrease the antihypertensive activities of Epoprostenol.
Bepridil Naxitamab may decrease the antihypertensive activities of Bepridil.
Hydralazine Naxitamab may decrease the antihypertensive activities of Hydralazine.
Bevantolol Naxitamab may decrease the antihypertensive activities of Bevantolol.
Practolol Naxitamab may decrease the antihypertensive activities of Practolol.
Polythiazide Naxitamab may decrease the antihypertensive activities of Polythiazide.
Cilazapril Naxitamab may decrease the antihypertensive activities of Cilazapril.
Saprisartan Naxitamab may decrease the antihypertensive activities of Saprisartan.
Spirapril Naxitamab may decrease the antihypertensive activities of Spirapril.
Penbutolol Naxitamab may decrease the antihypertensive activities of Penbutolol.
Mibefradil Naxitamab may decrease the antihypertensive activities of Mibefradil.
Oxprenolol Naxitamab may decrease the antihypertensive activities of Oxprenolol.
Pargyline Naxitamab may decrease the antihypertensive activities of Pargyline.
Dexpropranolol Naxitamab may decrease the antihypertensive activities of Dexpropranolol.
Tienilic acid Naxitamab may decrease the antihypertensive activities of Tienilic acid.
Debrisoquine Naxitamab may decrease the antihypertensive activities of Debrisoquine.

Target Protein

GD2 disialoganglioside

Referensi & Sumber

Artikel (PubMed)
  • PMID: 30326045
    Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS, Cheung NK: Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial. JAMA Oncol. 2018 Dec 1;4(12):1729-1735. doi: 10.1001/jamaoncol.2018.4005.
  • PMID: 29147617
    Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV: Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. Oncoimmunology. 2017 Jul 31;6(11):e1358331. doi: 10.1080/2162402X.2017.1358331. eCollection 2017.
  • PMID: 32052309
    Temrikar ZH, Suryawanshi S, Meibohm B: Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients. Paediatr Drugs. 2020 Apr;22(2):199-216. doi: 10.1007/s40272-020-00382-7.
  • PMID: 23702928
    Cheung NK, Dyer MA: Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013 Jun;13(6):397-411. doi: 10.1038/nrc3526.
  • PMID: 25851904
    Zhao Q, Ahmed M, Guo HF, Cheung IY, Cheung NK: Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8. J Biol Chem. 2015 May 22;290(21):13017-27. doi: 10.1074/jbc.M115.650903. Epub 2015 Apr 7.

Contoh Produk & Brand

Produk: 1 • International brands: 1
Produk
  • Danyelza
    Injection • 40 mg/10mL • Intravenous • US • Approved
International Brands
  • Danyelza

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul